![[Graphic News] Americano becomes most popular drink for Korean adults](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F07%2F02%2Fnews-p.v1.20250702.06811c5dca704b2a870ec64580865780_T1.gif&w=3840&q=100)
[Graphic News] Americano becomes most popular drink for Korean adults
Koreans older than one year consumed an average of 274.6 grams of beverages daily as of 2023, a rise of more than 20 percent from 223.5 grams in 2019. Men averaged 300 grams per day, while women consumed 247.2 grams. People in their 30s drank the most, averaging 415.3 grams daily - more than four glasses.
Unsweetened coffee, such as Americano, topped the list at 112.1 grams daily - an increase of 28.2 grams over five years. Carbonated drinks ranked second, with 48.9 grams consumed daily.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Ex-Celltrion veteran to head Daewoong's new biosimilar division
Korean traditional medicine powerhouse seeks new growth engine Daewoong Pharmaceutical said Tuesday that it has decided to launch a biosimilar business as the Korean traditional drug maker looks for new growth engines. Daewoong named Hong Seung-suh -- who led biosimilar R&D and global commercialization at Celltrion between 2002 and 2019, and has nearly 20 years of experience in the field -- as the head of its biosimilar business division. 'It's very meaningful that Daewoong Pharmaceutical, which has contributed to improving the health of Koreans over the last 80 years, is entering the biosimilar market,' said Hong. 'Biosimilar is a sector that can play a very important role in creating a medical environment in which anyone can receive treatment. Based on Daewoong Pharmaceutical's sales network and driving force, we will contribute to offering better accessibility to treatment for all patients in the world.' Biosimilar products, which are biologic medicines very similar to already approved reference biologics, are considered more affordable treatment options that can replace pricier drugs. As biosimilar products usually have shorter development periods and higher chances of approval compared to new drugs, they tend to reduce risk while bolstering cost competitiveness. According to global market analysts at IMARC Group, the global biosimilar market reached $26.5 billion last year and is expected to hit $185.1 billion by 2033. For its biosimilar business, Daewoong plans to not only strengthen its own development capabilities but also actively seek strategic partnerships both in Korea and overseas with other biosimilar players and contract development and manufacturing organizations, or CDMOs, as the drug maker aims to expand its product portfolio and enter major markets such as Europe and the United States in the long term to transform into a global bio company. 'As Daewoong Pharmaceutical boasts experience learned from developing a variety of medicines and commercializing them, and thanks to our global partnership capabilities, we will be able to demonstrate our distinctive ability to take action through not only self-development but also co-development in the biosimilar market,' said Park Seong-soo, CEO of Daewoong Pharmaceutical. 'Instead of being satisfied with short-term achievements, we plan to carry out our mid- to long-term strategies step-by-step with the goal of becoming an impactful player in the global market.'
Korea Herald
a day ago
- Korea Herald
100-day rule for newborns
For many Korean parents, bringing a newborn home from the hospital plays out like a covert mission. From the moment the baby leaves the hospital, every move is meticulously planned. Swaddled tightly in layers of blankets, the infant is swiftly ushered through the underground parking lot and into the car. There's no detour, only a direct drive home. Upon arriving the parking lot of their home, the parents rewrap the baby, shielding the child from sunlight and wind before making a quick dash indoors. And with that, the 100-day tradition of voluntary seclusion begins. In Korea, there is a long-standing tradition of keeping newborns indoors and limiting visitors during the first 100 days after birth. The practice is rooted in the belief that it helps protect the baby, whose immune system is not yet fully developed, from outside germs and infection. Back in the old days, infant mortality rates were high, and surviving the first 100 days of life was considered a major milestone. With significant advances in health care, the 100-day rule is less strictly followed by parents today. Yet as a deeply rooted tradition, it continues to spark debate among first-time parents. It also reveals a generational divide: When a baby just one or two months old is seen outside with their parents, older generations may frown upon it, vewing it as a reckless decision that prioritizes parental conveninence over the baby's safety. 'I'm a mom with a 54-day-old newborn. Is it okay to go outside for a walk? How far do you usually go?' one user asked on a local online parenting forum. For some parents, especially those caring for a newborn on their own, the 100-day confinement, though meant to protect the baby, can feel quite isolating and may even contribute to postpartum depression. The sense of loneliness is often amplified in a society where apartment living is the norm and neighbors tend to remain strangers. So if your Korean friend recently had a baby and is not going outside like they are in full-on quarantine and turning down visitors, don't take it the wrong way. It's just the 100-day rule. cjh@
Korea Herald
6 days ago
- Korea Herald
In vitro fertilization nearly doubles in 5 years
Assisted reproductive technology rapidly becoming a new norm in the country with one of the lowest birth rates in the world Embryos produced via in vitro fertilization have surged by 83.2 percent in South Korea over the past five years, according to government data released Thursday, signaling the growing use of assisted reproductive technology in a country grappling with low birth rates. A total of 783,860 embryos were created through IVF in 2024, up from 427,818 in 2019, according to the Ministry of Health and Welfare data submitted to Rep. Kim Yoon of the ruling Democratic Party of Korea. The number has been steadily climbing since 2016, when 334,687 embryos were created, and surpassed 500,000 for the first time in 2021. The actual embryo transfer has also increased in recent years, although not as rapidly. Last year, 201,496 embryos were transferred for pregnancy, up 31.9 percent from 152,761 in 2019 and 56.6 percent from 128,672 in 2016. IVF is a procedure to aid pregnancy, where mature eggs are collected and fertilized by sperm in a laboratory setting. The fertilized eggs are transferred to a human body for pregnancy or cryopreserved for future use. As of December 2024, medical institutions across the country were storing 383,520 embryos, along with 133,926 unfertilized eggs and 56,967 vials of semen. However, most fertilized embryos end up being discarded. In 2024 alone, 533,266 embryos were destroyed, more than double the 260,506 discarded in 2019. Embryos may be discarded for various reasons, including being deemed unfit for pregnancy or upon request by the individuals who created them. Frozen embryos can theoretically be stored indefinitely if maintained properly, but most people only store them for up to 10 years. In vitro fertilization becoming more crucial, but controversy remains IVF is becoming an increasingly vital option in South Korea, where the average age of first-time mothers was 32.96 as of 2023. Advanced maternal age is medically defined as 35 or older, which means a substantial number of Korean couples are presumed to have some complications when trying to conceive naturally. Despite the many advantages of assisted pregnancy technology, some ethical questions are not yet covered by the Bioethics and Safety Act. Earlier in July, actor Lee Si-young revealed that she had gotten pregnant via embryo created with her ex-husband, despite his opposition. This is due to a loophole in the law: It mandates a written consent when creating embryos via in vitro fertilization, but has no clause on transferring the already-created embryos to the human body. The incident has touched off controversy about the bioethics of the embryo and in vitro fertilization, which is still a relatively new field in the world and particularly in South Korea. The Bioethics and Safety Act itself, which covers the matters related to embryos, was only enacted in 2004 and came into effect the following year.
